Alternatives to Osium AI

Physics-based simulation plus AI for molecular discovery across drug and materials design.

Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.

Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.

Clinical-stage AI drug discovery company running a wet-and-dry lab-in-the-loop engine with 2M weekly experiments and a 50+ PB phenomics dataset

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding, debugging, and controlling the internals of your AI models.

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.

Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.

Atomwise's APEX Protocol ML platform screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generative biology company designing protein therapeutics — antibodies, enzymes, cytokines — through a closed loop of machine learning and wet-lab biology.

Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.

All-in-human AI foundation models that predict brain activity and therapy response for CNS drug programs

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data for discovery teams.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.

Google's umbrella health initiative: consumer health info, research tools like AlphaFold, and clinical AI research.

Tempus is an AI precision oncology platform that pairs tumor DNA/RNA sequencing with a 7M+ de-identified clinical record library for treatment and trial

AI drug discovery company pairing Enchant v3 and NeuralPLexer with a weekly wet lab to push small-molecule candidates into the clinic.

AI-native biotech pairing 20+ petabytes of cellular experiments with population genetics to find causal drug targets

AI-guided protein engineering that co-optimizes binding, stability, activity, and expression using your own wet-lab data.

Cellino builds closed-loop, AI-guided bioprocessing hardware for personalized cell therapy manufacturing.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.

Preclinical biotech using causal AI models X-Cell and X-Atlas/Pisces to predict how biology responds to perturbation, from target to patient.

Clinical-stage TechBio company using cellular imaging and AI to discover drugs, with a Phase 1 MALT1 inhibitor and a Genentech neuroscience collaboration.

Dotmatics Luma: agentic AI that plans, executes, and completes R&D data analysis, report generation and platform configuration for multimodal scientific

Exscientia now lives inside Recursion — an AI drug discovery engine built on automated wet labs and a 50+ PB dataset.

Automated cloud lab for protein validation — binding, expression, and thermostability assays from $149 per protein.